Boehringer Ingelheim announces collaboration with MabGenesis to discover and develop novel monoclonal antibodies in canine

Ingelheim, Germany,

  • This collaboration aims to discover innovative therapeutic antibodies in canine using the MabGenesis’ platform technologies
  • Strengthening partnership to accelerate innovation is key in Boehringer Ingelheim’s R&D strategy

Ingelheim, Germany, January 18, 2022 – Boehringer Ingelheim, a global leader in animal health, and MabGenesis, a private biopharmaceutical company headquartered in Yokohama, Japan, announce that they have entered into a collaboration to discover and develop novel monoclonal antibodies for potential canine therapeutic treatments. Under the agreement, MabGenesis will apply its unique platform to the discovery of first-in-class candidate antibodies against targets of interest selected by Boehringer Ingelheim. Boehringer Ingelheim will have the right to develop and commercialize products resulting from the collaboration. Terms of the agreement were not disclosed.

“We are excited to partner with global animal health leader Boehringer Ingelheim as we feel we bring complementary expertise to this collaboration,” said Katsuhiro Shinjo, DVM, PhD, Chief Executive Officer of MabGenesis. “The combination of our innovative discovery platform, MOURA Library and IMPACT, and Boehringer Ingelheim’s capability and industry leadership will surely lead to the discovery of innovative canine therapeutic antibodies bringing benefits to animal health.”

By partnering, Boehringer Ingelheim is leveraging the wealth of complementary expertise and skills across the global community of scientists in both human and animal health to bring critical diversity to innovation. "Collaborating with innovative and entrepreneurial partners contributes to solving the biggest challenges in animal health. The new areas of science, such as stem cell therapeutics and species-specific monoclonal antibody technology, hold the key to revealing new ways to tackle disease, where limited or no treatment options exist, and provide the opportunity to unlock the next wave of transformational solutions," explained Frerich de Vries, Head of Business Development & Licensing at Boehringer Ingelheim Animal Health.

Stephen Martin, Head of Research, Boehringer Ingelheim Animal Health, added: “We believe that collaboration and shared innovation can lead to groundbreaking solutions to better predict, prevent, detect and treat diseases. This strategic partnership is another example of our commitment to address unmet needs in the animal health market with the aim to improve the lives of animals and humans.”

MabGenesis logo


About MabGenesis Inc.

MabGenesis Inc. is a biopharmaceutical startup that delivers first-in-class and best-in-class therapeutic monoclonal antibodies for human and animals using technologies established by 30+ years of academic research. By using the innovative technology platform, high-quality phage display antibody libraries (MOURA Libraries) and efficient antibody isolation technology (IMPACT), MabGenesis makes it possible to isolate species-specific monoclonal antibodies rapidly and efficiently. MabGenesis Inc. is a private company headquartered in Yokohama, Japan. For more information visit: https://mabgenesis.com/en

Boehringer Ingelheim Animal Health

The lives of animals and humans are interconnected in deep and complex ways. We know that when animals are healthy, humans are healthier too. Across the globe, our 9,700 employees are dedicated to delivering value through innovation, thus enhancing the well-being of both.

Respect for animals, humans and the environment is at the heart of what we do. We develop solutions and provide services to protect animals from disease and pain. We support our customers in taking care of the health of their animals and protect our communities against life- and society-threatening diseases.

Boehringer Ingelheim Animal Health is the second largest animal health business in the world, with net sales of 4.1 billion euros in 2020 and presence in more than 150 countries. For more information visit: www.boehringer-ingelheim.com/animal-health.

Boehringer Ingelheim

Boehringer Ingelheim is working on breakthrough therapies that improve the lives of humans and animals. As a leading research-driven biopharmaceutical company, the company creates value through innovation in areas of high unmet medical need. Founded in 1885 and family-owned ever since, Boehringer Ingelheim takes a long-term perspective. Around 52,000 employees serve more than 130 markets in the three business areas, Human Pharma, Animal Health, and Biopharmaceutical Contract Manufacturing. Learn more at www.boehringer-ingelheim.com.

Intended audiences:

This press release is issued from our Corporate Headquarters in Ingelheim, Germany and is intended to provide information about our global business. Please be aware that information relating to the approval status and labels of approved products may vary from country to country, and a country-specific press release on this topic may have been issued in the countries where we do business.

Media Contacts

Services

Print this Press Release

Tags

Press Release Subscription

Signup here to the Boehringer Ingelheim Newsletter to receive press-releases via email.